CA2142325A1 - Vecteur retroviral recombinant agissant contre felv et (ou) fiv - Google Patents

Vecteur retroviral recombinant agissant contre felv et (ou) fiv

Info

Publication number: CA2142325A1
Authority: CA; Canada
Prior art keywords: virus; feline; vector construct; expression; directs
Prior art date: 1992-09-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002142325A

Other languages

English (en)

Inventor

William T. L. Lee

John J. Serbin

Douglas J. Jolly

Jack R. Barber

Sunil Chada

Stephen M. W. Chang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis Vaccines and Diagnostics Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-21

Filing date

1993-09-21

Publication date

1994-03-31

1993-09-21 Application filed by Individual filed Critical Individual

1994-03-31 Publication of CA2142325A1 publication Critical patent/CA2142325A1/fr

Status Abandoned legal-status Critical Current

Links

239000013598 vector Substances 0.000 title claims abstract description 125
230000001177 retroviral effect Effects 0.000 title description 27
241000282324 Felis Species 0.000 claims abstract description 85
241000713800 Feline immunodeficiency virus Species 0.000 claims abstract description 64
239000000427 antigen Substances 0.000 claims abstract description 53
102000036639 antigens Human genes 0.000 claims abstract description 53
108091007433 antigens Proteins 0.000 claims abstract description 53
230000014509 gene expression Effects 0.000 claims abstract description 40
241000714165 Feline leukemia virus Species 0.000 claims abstract description 26
230000003405 preventing effect Effects 0.000 claims abstract description 19
230000009385 viral infection Effects 0.000 claims abstract description 16
230000002163 immunogen Effects 0.000 claims abstract description 9
241000700605 Viruses Species 0.000 claims description 73
241001430294 unidentified retrovirus Species 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 11
241000725303 Human immunodeficiency virus Species 0.000 claims description 9
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 6
241000709661 Enterovirus Species 0.000 claims description 5
241000991587 Enterovirus C Species 0.000 claims description 5
241000714201 Feline calicivirus Species 0.000 claims description 5
201000005505 Measles Diseases 0.000 claims description 5
241000710960 Sindbis virus Species 0.000 claims description 5
241000701161 unidentified adenovirus Species 0.000 claims description 5
241001529453 unidentified herpesvirus Species 0.000 claims description 5
241000701915 Feline panleukopenia virus Species 0.000 claims description 4
241000125945 Protoparvovirus Species 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
241000712461 unidentified influenza virus Species 0.000 claims description 4
241000701087 Felid alphaherpesvirus 1 Species 0.000 claims description 3
241000712079 Measles morbillivirus Species 0.000 claims description 3
230000004186 co-expression Effects 0.000 claims description 3
241000711798 Rabies lyssavirus Species 0.000 claims description 2
238000000034 method Methods 0.000 abstract description 33
230000024932 T cell mediated immunity Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 113
108090000623 proteins and genes Proteins 0.000 description 40
239000012634 fragment Substances 0.000 description 32
239000013615 primer Substances 0.000 description 31
241000282326 Felis catus Species 0.000 description 30
238000003556 assay Methods 0.000 description 26
239000013612 plasmid Substances 0.000 description 21
108020004414 DNA Proteins 0.000 description 19
230000004044 response Effects 0.000 description 19
208000015181 infectious disease Diseases 0.000 description 18
102000004169 proteins and genes Human genes 0.000 description 18
239000000203 mixture Substances 0.000 description 15
108020004707 nucleic acids Proteins 0.000 description 14
102000039446 nucleic acids Human genes 0.000 description 14
150000007523 nucleic acids Chemical class 0.000 description 14
241000030538 Thecla Species 0.000 description 13
239000002299 complementary DNA Substances 0.000 description 13
101100013899 Feline leukemia virus gag gene Proteins 0.000 description 12
241000699660 Mus musculus Species 0.000 description 12
238000011580 nude mouse model Methods 0.000 description 12
230000003612 virological effect Effects 0.000 description 12
238000010276 construction Methods 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 10
238000012360 testing method Methods 0.000 description 10
229920001817 Agar Polymers 0.000 description 9
239000008272 agar Substances 0.000 description 9
230000001413 cellular effect Effects 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
239000002609 medium Substances 0.000 description 9
230000000692 anti-sense effect Effects 0.000 description 8
201000010099 disease Diseases 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
239000000047 product Substances 0.000 description 8
229960005486 vaccine Drugs 0.000 description 8
108010017826 DNA Polymerase I Proteins 0.000 description 7
102000004594 DNA Polymerase I Human genes 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
108010002350 Interleukin-2 Proteins 0.000 description 7
102000000588 Interleukin-2 Human genes 0.000 description 7
230000000295 complement effect Effects 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000000243 solution Substances 0.000 description 7
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
108020004705 Codon Proteins 0.000 description 6
102000053602 DNA Human genes 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
239000000969 carrier Substances 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
238000001262 western blot Methods 0.000 description 6
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
239000012636 effector Substances 0.000 description 5
239000003550 marker Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
231100001221 nontumorigenic Toxicity 0.000 description 5
238000007747 plating Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
238000010361 transduction Methods 0.000 description 5
230000026683 transduction Effects 0.000 description 5
231100000588 tumorigenic Toxicity 0.000 description 5
230000000381 tumorigenic effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
208000030507 AIDS Diseases 0.000 description 4
238000001712 DNA sequencing Methods 0.000 description 4
102000014150 Interferons Human genes 0.000 description 4
108010050904 Interferons Proteins 0.000 description 4
108091054437 MHC class I family Proteins 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
206010058874 Viraemia Diseases 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
239000012737 fresh medium Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
238000011160 research Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
101710132601 Capsid protein Proteins 0.000 description 3
241000702421 Dependoparvovirus Species 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102100034349 Integrase Human genes 0.000 description 3
102000004388 Interleukin-4 Human genes 0.000 description 3
108090000978 Interleukin-4 Proteins 0.000 description 3
102000004889 Interleukin-6 Human genes 0.000 description 3
108090001005 Interleukin-6 Proteins 0.000 description 3
108091054438 MHC class II family Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
241001674048 Phthiraptera Species 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
230000005757 colony formation Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 3
244000052769 pathogen Species 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000011282 treatment Methods 0.000 description 3
230000005740 tumor formation Effects 0.000 description 3
-1 ~-microglobulin Proteins 0.000 description 3
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
229940124718 AIDS vaccine Drugs 0.000 description 2
101001002617 Bos taurus Interleukin-2 Proteins 0.000 description 2
108010084313 CD58 Antigens Proteins 0.000 description 2
241000701931 Canine parvovirus Species 0.000 description 2
108090000565 Capsid Proteins Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010062580 Concanavalin A Proteins 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
201000008808 Fibrosarcoma Diseases 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
229920000209 Hexadimethrine bromide Polymers 0.000 description 2
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
101710135007 Histone-like protein p6 Proteins 0.000 description 2
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
102100022339 Integrin alpha-L Human genes 0.000 description 2
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 2
102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
102000043129 MHC class I family Human genes 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000005431 Molecular Chaperones Human genes 0.000 description 2
108010006519 Molecular Chaperones Proteins 0.000 description 2
208000037581 Persistent Infection Diseases 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
108010071390 Serum Albumin Proteins 0.000 description 2
102000007562 Serum Albumin Human genes 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
229960004150 aciclovir Drugs 0.000 description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
102000023732 binding proteins Human genes 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
208000010717 cat disease Diseases 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
230000034994 death Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
108700004025 env Genes Proteins 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
229960002518 gentamicin Drugs 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
229940028885 interleukin-4 Drugs 0.000 description 2
229940100601 interleukin-6 Drugs 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
201000002364 leukopenia Diseases 0.000 description 2
231100001022 leukopenia Toxicity 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
239000001397 quillaja saponaria molina bark Substances 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
229930182490 saponin Natural products 0.000 description 2
150000007949 saponins Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
229940031439 squalene Drugs 0.000 description 2
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
XFVULMDJZXYMSG-ZIYNGMLESA-N 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylic acid Chemical compound NC1=C(C(O)=O)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 XFVULMDJZXYMSG-ZIYNGMLESA-N 0.000 description 1
DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
229940124321 AIDS medicine Drugs 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000178270 Canarypox virus Species 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108020001019 DNA Primers Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
101710177291 Gag polyprotein Proteins 0.000 description 1
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
240000004153 Hibiscus sabdariffa Species 0.000 description 1
235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101150017040 I gene Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
241000186781 Listeria Species 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
208000014767 Myeloproliferative disease Diseases 0.000 description 1
241001045988 Neogene Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
238000012220 PCR site-directed mutagenesis Methods 0.000 description 1
LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
108010035235 Phleomycins Proteins 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
241001068263 Replication competent viruses Species 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
241000287219 Serinus canaria Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
210000000662 T-lymphocyte subset Anatomy 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
241000223997 Toxoplasma gondii Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
SUPKOOSCJHTBAH-UHFFFAOYSA-N adefovir Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
230000000798 anti-retroviral effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
235000021028 berry Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
201000005547 chronic conjunctivitis Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
231100001021 decreased hematocrit Toxicity 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
101150030339 env gene Proteins 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
239000013642 negative control Substances 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000004853 protein function Effects 0.000 description 1
239000003725 proteoliposome Substances 0.000 description 1
108010030416 proteoliposomes Proteins 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000010907 stover Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229950008418 talipexole Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000013519 translation Methods 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Ceramic Products (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

CA002142325A 1992-09-21 1993-09-21 Vecteur retroviral recombinant agissant contre felv et (ou) fiv Abandoned CA2142325A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94835892A	1992-09-21	1992-09-21
US07/948,358		1992-09-21

Publications (1)

Publication Number	Publication Date
CA2142325A1 true CA2142325A1 (fr)	1994-03-31

Family

ID=25487709

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002142325A Abandoned CA2142325A1 (fr)	1992-09-21	1993-09-21	Vecteur retroviral recombinant agissant contre felv et (ou) fiv

Country Status (5)

Country	Link
EP (1)	EP0662139A1 (fr)
JP (1)	JPH08501452A (fr)
AU (1)	AU5138293A (fr)
CA (1)	CA2142325A1 (fr)
WO (1)	WO1994006921A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2234995A (en) *	1994-04-29	1995-11-29	Pharmacia & Upjohn Company	Feline immunodeficiency virus vaccine
US5820869A (en) *	1995-06-07	1998-10-13	American Home Products Corporation	Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US6300118B1 (en)	1995-06-07	2001-10-09	American Home Products Corporation	Plasmids comprising a genetically altered feline immunodeficiency virus genome
FR2751223B1 (fr) *	1996-07-19	1998-12-04	Rhone Merieux	Formule de vaccin polynucleotidique felin
WO1998044938A1 (fr)	1997-04-10	1998-10-15	University Of Southern California	Proteines modifiees se fixant a des composants de matrice extracellulaires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10399032I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
ATE130631T1 (de) *	1988-08-08	1995-12-15	Upjohn Co	Verfahren zur isolierung für thymidin-kinase der herpesvirus kodierenden dns.
GB8901778D0 (en) *	1989-01-27	1989-03-15	Univ Court Of The University O	Manipulatory technique

1993
- 1993-09-21 CA CA002142325A patent/CA2142325A1/fr not_active Abandoned
- 1993-09-21 JP JP6508444A patent/JPH08501452A/ja active Pending
- 1993-09-21 AU AU51382/93A patent/AU5138293A/en not_active Abandoned
- 1993-09-21 EP EP93922364A patent/EP0662139A1/fr not_active Withdrawn
- 1993-09-21 WO PCT/US1993/009070 patent/WO1994006921A1/fr not_active Ceased

Also Published As

Publication number	Publication date
WO1994006921A1 (fr)	1994-03-31
JPH08501452A (ja)	1996-02-20
EP0662139A1 (fr)	1995-07-12
AU5138293A (en)	1994-04-12

Legal Events

Date	Code	Title	Description
1999-09-21	FZDE	Discontinued
2023-10-24	FZDE	Discontinued	Effective date: 19990921

Publication	Publication Date	Title
EP0334301B1 (fr)	1998-12-23	Rétrovirus recombinants
EP0778888B1 (fr)	2006-06-21	Particules retroviriformes non infectieuses a marquage antigenique
ES2341429T3 (es)	2010-06-21	Mejoras en las respuestas inmunitarias al vih o relacionadas con las mismas.
Montelaro et al.	1993	Equine retroviruses
US5741492A (en)	1998-04-21	Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
JP5033303B2 (ja)	2012-09-26	抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
US6451322B1 (en)	2002-09-17	Retrovirus like particles made non infectious by a plurality of mutations
US5856185A (en)	1999-01-05	Method for making reflection defective retroviral vectors for infecting human cells
US6004799A (en)	1999-12-21	Recombinant live feline immunodeficiency virus and proviral DNA vaccines
JPH06508037A (ja)	1994-09-14	免疫不全ウイルス組換えポックスウイルスワクチン
JP2004502445A (ja)	2004-01-29	抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびその使用
Willems et al.	1995	The YXXL signalling motifs of the bovine leukemia virus transmembrane protein are required for in vivo infection and maintenance of high viral loads
JP2004537303A (ja)	2004-12-16	抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
EP0625204B1 (fr)	2002-06-19	Therapeutique de l'hepatite
DE69527544T2 (de)	2003-03-20	Kombinationsvektoren zum austragen von genmaterial
CA2142325A1 (fr)	1994-03-31	Vecteur retroviral recombinant agissant contre felv et (ou) fiv
WO2001008702A2 (fr)	2001-02-08	Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie
ES2252918T3 (es)	2006-05-16	Cepa fiv-141 del virus de la inmunodeficiencia felina y sus usos.
US8603490B2 (en)	2013-12-10	Modified human immunodeficiency virus clade C envelope polypeptides obtained from a zambian isolate
IL139360A (en)	2007-07-24	Viral chimeras consisting of genetic units from CAEV and HIV-1
EP1007687A1 (fr)	2000-06-14	Vaccin anti-vif
US20060067948A1 (en)	2006-03-30	Viral vectors
AU2002249393A1 (en)	2002-10-15	Viral vectors
HK1046428B (en)	2008-08-15	The genome of the hiv-1 inter-subtype (c/b') and use thereof